Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thai Professor Urges Greater, Not Less, Use Of Tamiflu For Bird Flu

This article was originally published in PharmAsia News

Executive Summary

A Thailand professor suggests healthcare providers prescribe a higher dose of Roche's Tamiflu (oseltamivir) for resistant strains of the H5N1 avian influenza virus, not avoid its use altogether. Nicholas White of Mahidol University wrote in a medical journal that despite the threat of resistance, higher doses of the drug should be used because of its fatality rate - 262 deaths out of 433 people infected since 2003. He said common sense argues for higher doses to reduce the fatality of infections. White's article drew criticism from other medical experts who said it was dangerous to rely on a single flu drug such as Tamiflu. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel